Exacerbation of Subacute Cutaneous Lupus Erythematosus Following Vaccination with BNT162b2 mRNA Vaccine

    June 2021 in “ Dermatologic Therapy ”
    Dennis Niebel, Veronika Ralser‐Isselstein, Kristel Jaschke … Joerg Wenzel
    Studysummary This study reports that a patient with subacute cutaneous lupus erythematosus experienced disease exacerbation after the first dose of the BNT162b2 mRNA COVID-19 vaccine, but tolerated the second dose without adverse reactions.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →